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Abstract 
 
Background:  Nosocomial infections are an increasing problem in the United States 
with a reported 2 million American patients per year developing an infection as a result of 
their hospital stay (3).  Newly synthesized derivatives of two classes of anti-cancer 
drugs known as anthracyclines and indolocarbazoles have recently been tested against 
leukemia K562 cells, colon cancer SW620 cells (15-19) and now Escherichia coli, 
Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis and 
Streptococcus pyogenes.  Methods:  Minimum Inhibitory Concentration (MIC) values 
were collected for 40 newly synthesized anticancer agents via microdilution antimicrobial 
susceptibility testing.  Results:  Thirteen anthracycline derivatives and three 
indolocarbazoles derivatives seemed to show an inhibitory effect to either one or all of 
the gram-positive organisms tested.  The antimicrobial activities obtained in this study 
were then compared to the anticancer activities published in previous literature, resulting 
in the discovery of five anthracycline and one indolocarbazole derivatives which 
demonstrate good inhibition against both bacterial and cancer cell proliferation.  
Conclusion:  The present study dealing with the effects of these drugs on prokaryotic 
system may help distinguish which drugs could be able to minimize a patient’s chance of 
acquiring a bacterial infection while in use during chemotherapy.  In addition, these 
studies could also provide more information in terms of the structure-activity relationship 
(SAR) between the drugs and their designated cellular targets. 
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Chapter 1: Introduction 
Nosocomial infections have become a very significant problem in clinical settings all 
across the world.  For example, in Intensive Care Unit (ICU) hospital settings 
(representing 8 % to 15% of hospital admissions), patients suffer from a substantially 
higher percentage of nosocomial infections, leading to increases in morbidity, mortality 
and financial cost (12).  Some of these ICU patients may be cancer patients that are 
undergoing (or had previously undergone) chemotherapy.  Due to the negative effects 
that chemotherapy drugs have on the immune system, patients undergoing chemotherapy 
have a higher chance of acquiring nosocomial infections as a result of their hospital stay 
(14).  As a result, the importance of preventing infection in cancer patients undergoing 
chemotherapy is significant. 
Anthracyclines, a class of drugs known to target DNA topoisomerase II in eukaryotes, 
are known to be some of the most effective drugs against a wide variety of solid tumors 
in human patients (2).  Daunomycin and doxorubicin are two anthracyclines that have 
been widely used in clinical settings since the 1970s (13).  Currently, the common 
clinical administration of daunomycin is daily intravenous injections of 30-60 mg/m2 for 
3-6 days.  This dosage is not to exceed a cumulative-lifetime dose of 900 mg/m2 in 
adults and 25 mg/kg in children (25). The mechanism of action for these drugs is believed 
to involve the drug’s intercalation with DNA and stabilization of a topoisomerase 
II-DNA-drug ternary complex.  Due to the growing demand for the introduction of new 
anthracycline derivatives, anthracyclines have been extensively researched in the hope of 
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finding more potent agents that overcome multidrug resistance and show reduced 
cardiotoxicity (4, 7).  Recently, several novel anthracycline derivatives have been 
synthesized and tested against a variety of normal and drug resistant cancer cell lines 
(15-18).  Some of these results have even discovered a reduction in cardiotoxicity with 
newly synthesized disaccharide derivatives, a major problem that most anthracycline 
monosaccharides such as Daunomycin cannot overcome (23, 24). 
Indolocarbazoles are a newer class of anticancer drugs than the more well known 
anthracyclines used since the 1970s.  Indolocarbazoles are most well known for their 
inhibitory role towards Topoisomerase I (21).  Topoisomerase I is responsible for 
condensing and opening chromosomes during mitosis which allows for the replication 
and transcription of DNA (21).  Indolocarbazoles work almost in the same way as 
anthracyclines by intercalating in between the DNA and stabilizing the 
DNA-Topoisomerase I-Drug complex (22).  This stabilization prevents the 
Topoisomerase I enzyme from cleaving and religating the DNA strands, causing 
apoptosis.  Another documented target of the indolocarbazoles is protein kinase C (22).  
The most famous of the indolocarbazoles is rebeccamycin and several derivatives have 
been synthesized in the hope of creating more potent Topoisomerase I inhibitors.  
Currently, rebeccamycin is clinically administered at 16-128 mg/m2/week for several 
weeks, with a maximum tolerated dosage (MTD) of 572 mg/m2 (26).  This study 
measures the antimicrobial activity of seven new indolocarbazole derivatives that have 
recently been synthesized and tested against common cancer cell lines (19).  In addition, 
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one of the most favorable qualities that these anticancer agents possess over the 
anthracycline family is reduced cardiotoxicity. 
 Targeting nosocomial infections requires identifying the bacteria that are known 
to cause such infections in hospital patients.  In ICU settings, it has been discovered that 
the urinary tract, pneumonia and primary bloodstream are the most commonly infected 
areas, constituting 77% of all nosocomial infection sites (11).  Of those commonly 
infected areas, coagulase-negative staphylococci constitute 36% of bloodstream 
infections while enterococci constitute 16% of bloodstream infections, 14% of urinary 
tract infections and 43% of cardiovascular infections.  In the case of individual 
organisms, S. aureus, P. aeruginosa and E. coli are responsible for a combined 19% of 
bloodstream infections, 45% of pneumonia infections and 16% of urinary tract infections 
(11).  This study focuses on inhibiting E. coli, P. aeruginosa, S. aureus, E. faecalis and S. 
pyogenes due to their obvious role in hospital acquired infections.  With the known 
inhibitory potential of doxorubicin, daunomycin (6, 14) and rebeccamycin (21, 22) 
against gram positive organisms, this study shows similar inhibitory roles concerning 
newly synthesized anticancer agents against similar prokaryotes.  By exploiting these 
bacterial-cancer inhibitory effects, this study has the potential to discover which of these 
new anticancer derivatives have the ability to inhibit common nosocomial bacteria for the 
possible prevention of infections in patients who are administered these drugs during 
cancer chemotherapy.  Our aim is to test these anthracycline and indolocarbazole 
derivatives against infectious bacteria that have been known to play significant roles in 
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nosocomial infections.  Since it has been reported that anticancer drugs may be 
antagonistic in the action of several antibiotics (6, 8, 9, 10) and that anthracycline and 
indolocarbazole agents have antibacterial activity (5, 6, 14), the significance of 
antibacterial testing with new anticancer derivatives may help find new therapeutic ways 
of treating cancer patients. 
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Chapter 2: Materials and Methods 
Bacterial isolates.  E. coli ATCC 25922, P. aeruginosa ATCC 27853, S. aureus 
ATCC 29212, E. faecalis ATCC 29212 and S. pyogenes ATCC 19615 were the reference 
strains used in the antimicrobial susceptibility testing.  In addition, Erythromycin, 
Ampicillin and Daunomycin were tested against all six strains and compared with 
literature values (1, 6) for quality control reasons.   
Anticancer Derivatives.  All anticancer derivatives were synthesized at The Ohio 
State University Biochemistry Department, Columbus, Ohio using procedures specified 
in previous literature (15-19).  Stock solutions were prepared by dissolving 2.0 mg of 
each purified drug solid in 750 µl of DMSO.  Erythromycin, Ampicillin and 
Daunomycin were obtained as reagent grade powders and stock solutions of each were 
prepared in the same fashion as the anthracycline derivatives.  The resulting 2667 µg/ml 
stock solutions were stored in 4o C refrigeration for no longer than 30 days.  For 
experimentation, 25 µl of each stock solution was individually diluted in 975 µl 
Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, Michigan) to afford a 
concentration of 66 µg/ml.  The antimicrobial concentration range tested for the MIC 
determinations of each individual drug against each individual organism was 33 µg/ml to 
0.125 µg/ml.   
MIC determination.  The minimum inhibitory concentrations (MICs) were 
determined via a microdilution method that involved sterile 24-well plates (Corning).  E. 
coli, P. aeruginosa, S. aureus and E. faecalis were incubated on Tryptic soy agar (TSA; 
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Difco Laboratories, Detroit, Michigan) overnight and stored at 4o C for no longer than 40 
days.  TSA was made by mixing 10 grams of powder into 250 ml of distilled water.  
This solution was then brought to a boil over a hot plate and heated until all the powder 
had dissolved.  This mixture was then placed into an autoclave for 20 minutes at 120o C 
removed afterwards until the solution cooled down to 50o C.  Just before the TSA 
solution hardens it is transferred over to Petri dishes and incubated overnight to check for 
any contamination.  S. pyogenes was incubated in TSA with 5% Defibrinated Horse 
blood overnight and stored at 4o C for no longer than 30 days.  For making TSA with 
5% Defibrinated Horse blood, the blood is added to the agar right before the TSA hardens 
and after it has cooled down to 50o C.   
Serial twofold dilutions of the drugs in MHB were used for the testing of E. coli, P. 
aeruginosa, S. aureus, E. faecalis, and S. pyogenes (Figure 1 represents a 24-well plate 
containing with each well’s individual contents.  The first two rows of the plate are used 
for one drug while the other two are used for another drug.  One plate tests two drugs 
against one organism).  This two-fold dilution technique was done by first transferring 
50 ml of the 2667µg/ml stock solutions into 925 ml of sterile MHB in a centrifuge tube.  
500 µl of the resulting 132 µg/ml drug concentration is then mixed with a sterile 500 µl 
of MHB in well 2.  500 µl of the resulting dilution is then transferred to well 3, mixed, 
and the same is done all the way down to well 8, after which 500 µl is removed from well 
8.  This stepwise mixture and transfer creates a concentration gradient from 66 
µg/ml-0.25 µg/ml spanning wells 2-10, respectively.  After the addition of 500 µl of 
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inocula to wells 2-10 later in the procedure, the resulting concentration gradient spans 33 
µg/ml-0.125 µg/ml (wells 2-10, respectively).  Well 1 is used as a sterile control while 
well 12 is used as an inoculated control.   
To achieve the necessary cell suspension density, each organism was individually 
incubated in 10 ml of MHB at 37o C using an incubator shaker until a concentration of 2 
X 105 cells/ml was obtained (~100 minutes for each organism).  This length of time was 
found by doing individual growth curves for each individual organism.  The resulting 
inocula were transferred to their individual well plates containing the designated drug 
dilutions (500 µl of cell suspension was added to wells 2-10, 1000 µl was added to well 
12).  Lastly, the well plates were incubated for 20–24 hrs at 37o C, after which the plates 
were observed macroscopically for growth.  Tests were repeated at least two times for 
additional quality control.  The technique was confirmed by testing Ampicillin and 
Erythromycin against the same reference strains used in this study and comparing it to 
literature MIC values (18). 
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Figure 1: A model 24-well plate containing divided into two halves.  
1.  1000 µl of 
MHB (Sterile 
Control) 
2.  500 µl of  
Inoculum and 
500 µl of MHB 
3.  500 µl of 
Inoculum and 
500 µl of MHB 
4.  500 µl of 
Inoculum and 
500 µl of MHB 
5.  500 µl of 
Inoculum and 
500 µl of MHB 
6.  500 µl of 
Inoculum and 
500 µl of MHB 
7.  500 µl of 
Inoculum and 
500 µl of MHB 
8.  500 µl of 
Inoculum and 
500 µl of MHB 
9.  500 µl of 
Inoculum and 
500 µl of MHB 
10.  500 µl of 
Inoculum and 
500 µl of MHB 
11.  Blank 12.  1000 µl of 
Inoculum 
(Inoculated Control) 
1.  1000 µl of 
MHB (Sterile 
Control) 
2.  500 µl of 
Inoculum and 
500 µl of MHB 
3.  500 µl of 
Inoculum and 
500 µl of MHB 
4.  500 µl of 
Inoculum and 
500 µl of MHB 
5.  500 µl of 
Inoculum and 
500 µl of MHB 
6.  500 µl of 
Inoculum and 
500 µl of MHB 
7.  500 µl of 
Inoculum and 
500 µl of MHB 
8.  500 µl of 
Inoculum and 
500 µl of MHB 
9.  500 µl of 
Inoculum and 
500 µl of MHB 
10.  500 µl of 
Inoculum and 
500 µl of MHB 
11.  Blank 12.  1000 µl of 
Inoculum 
(Inoculated Control) 
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Chapter 3: Results 
 
 
OMe O
O OH
OH
OH
OH
O
OMe O
O OH
OH
O
OH
O
O
MeO
HO
OMe O
O OH
OH
O
OH
O
O
HO
OH
OMe O
O OH
OH
O
OH
O
O
N3
OMe O
O OH
OH
O
OH
O
O
HO
HO
OH
3
OMe O
O OH
OH
O
NH2HO
OH
O
O
21
OMe O
O OH
OH
O
OH
O
O
HO
OMe
OMe O
O OH
OH
O
OH
O
O
HO
65
4
87  
Figure 2.  Drugs 1-8 represent monosaccharide anthracyclines with Drug 1 representing 
Daunorubicin (Daunomycin).  
 
 
 
Table 1.  MIC and IC50 values for daunomycin and seven monosaccharide derivatives 
 
Antimicrobial MIC (µg/mL) Monosacch-
aride 
Cmpds. 
Series 1 
S. 
aureus 
E. 
faecalis 
S. 
pyogenes 
Anti-cancera 
IC50 (nM) 
1 4 4 0.25 15.6 
2 > 33 > 33 > 33 > 2000 
3 33 33 33 104 
4 > 33 > 33 > 33 > 1000 
5 > 33 > 33 > 33 > 1000 
6 > 33 > 33 > 33 350 
7 > 33 > 33 > 33 > 1000 
8 > 33 > 33 2 265 
a. Cytotoxicity of compounds 1–8 on colon cancer SW620 cells by MTS assay 
(cell survival is compared to control group without treatment of any drugs. ) 
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Figure 3.  Drug 9 represents the monosaccharide ADNR (One substituent derivative of Daunomycin).  
Drugs 10-13 represent monosaccharide derivatives with an attached triazole group at the 3’ carbon on 
the primary sugar bound to the anthracycline conjugated ring system. 
 
 
 
 
 
Table 2.  MIC and IC50 values for daunomycin and five monosaccharide derivatives 
 
Antimicrobial MIC (µg/mL) Monosacch-
aride 
Cmpds. 
Series 2 
S. 
aureus 
E. 
faecalis 
S. 
pyogenes 
Anti-cancera 
IC50 (nM) 
1 4 4 0.25 15.6 
9 > 33 > 33 > 33 75 
10 > 33 > 33 2 ~1000 
11 > 33 > 33 4 ~ 700 
12 > 33 > 33 4 ~ 400 
13 > 33 > 33 4 ~ 400 
a. Cytotoxicity of compounds 1, 9–13 on leukemia K562 cells by MTS assay 
(cell survival is compared to control group without treatment of any drugs. ) 
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Figure 4.  Drug 1 represents Daunomycin while Drugs 14-21 represent dissacharide derivatives with 
a common amine group attached to the 3’ position of the primary sugar bound to the anthracycline 
conjugated ring system. 
 
 
 
Table 3.  MIC and IC50 values for daunomycin and eight disaccharide derivatives 
 
Antimicrobial MIC (µg/mL) Disacch-
aride 
Cmpds. 
Series 3 
S. 
aureus 
E. 
faecalis 
S. 
pyogenes 
Anti- 
cancera 
IC50 (nM) 
1 4 4 0.25 15.6 
14 4 8 4 39.5 
15 8 8 1 45.8 
16 4 4 2 44.3 
17 > 33 > 33 > 33 1531.6 
18 4 8 2 21.0 
19 > 33 > 33 > 33 1378.3 
20 > 33 > 33 8 >4000 
21 4 4 2 31.3 
a. Cytotoxicity of compounds 1, 14–21 on leukemia K562 cells by MTS 
assay (cell survival is compared to control group without treatment 
of any drugs). 
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Figure 5.  Drugs 22-27 represent dissacharide anthracycline derivatives containing an azido group 
attached to the 3’ carbon on the primary sugar directly bound to the anthracycline conjugated ring 
system. 
 
 
 
 
Table 4.  MIC and IC50 values for daunomycin and six disaccharide derivatives 
 
Antimicrobial MIC (µg/mL) Disacch-
aride 
Cmpds. 
Series 4 
S. 
aureus 
E. 
faecalis 
S. 
pyogenes 
Anti- 
cancera 
IC50 
(nM) 
1 4 4 0.25 15.6 
22 > 33 > 33 > 33 790 
23 > 33 > 33 4 290 
24 > 33 > 33 > 33 280 
25 > 33 > 33 > 33 220 
26 > 33 > 33 > 33 450 
27 > 33 > 33 > 33 1132 
a. Cytotoxicity of compounds 1, 22–27 on leukemia K562 cells by MTS 
assay (cell survival is compared to control group without treatment 
of any drugs). 
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Figure 6.  Drugs 28-34 represent various anthracycline dimmer derivatives linked together via ether, 
amide and sugar groups. 
 
 
Table 5.  MIC and IC50 values for daunomycin and seven dimer derivatives 
 
Antimicrobial MIC (µg/mL)  
Dimer 
Cmpds. 
Series 5 
 
S. 
aureus 
E. 
faecalis 
S. 
pyogenes 
Anti- 
cancera 
IC50 (µM) 
1 4 4 0.25 15.6 
28 > 33 > 33 > 33 > 5 
29 > 33 > 33 > 33 4 
30 > 33 > 33 > 33 4 
31 > 33 > 33 > 33 N.A.b 
32 > 33 > 33 > 33 N.A. 
33 > 33 > 33 > 33 N.A. 
34 > 33 > 33 > 33 > 5 
a. Cytotoxicity of compounds 1, 28–34 on leukemia K562 cells by MTS 
assay (cell survival is compared to control group without treatment 
of any drugs).  B. N.A., not active 
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Figure 7.  Drug 35 represents Rebeccamycin while Drugs 36-42 represent monosaccharide 
indolocarbazole derivatives. 
 
 
a. Cytotoxicity of compounds 1, 28–34 on leukemia K562 cells by MTS
assay (cell survival is compared to control group without treatment
of any drugs).  b. N.A., not active
244> 33842
324> 33841
130.52140
34> 33> 33> 3339
2> 33> 33> 3338
> 100> 33> 33> 3337
> 100> 33> 33> 3336
4NA   NANAb35
S.
pyogenes
E.
faecalis
S.
aureus
Anticancera
IC50 (µM)
Antimicrobial MIC (µg/mL)Rebeccamy-
cin 
Derivatives
Table 6.  MIC and IC50 values for rebeccamycin and seven rebeccamycin derivatives
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Chapter 4: Discussion 
  Ampicillin, Erythromycin and Daunomycin (drug 1) all demonstrated antibacterial 
activity.  Ampicillin was found to inhibit S. aureus at 0.25 µg/ml, E. faecalis at 1 µg/ml 
and S. pyogenes at less then 0.125 µg/ml.  Erythromycin inhibited S. aureus and E. 
faecalis at 0.5 µg/ml, S. pyogenes at less then 0.125 µg/ml and E. coli at 4 µg/ml.   
Figures 2-7 represent all the anthracycline drugs tested against the three 
gram-positive bacteria in the study.  Figure 6 represents the seven indolocarbazole 
derivatives tested, with drug 35 representing the original rebeccamycin (a drug that was 
not tested in our study).  It was observed that none of the drug derivatives (including 
daunomycin) tested worked on gram-negative organisms (E. coli and P. aeruginosa).  
The values in Tables 1-6 correspond to Figs. 2-7, respectively.  Tables 1-6 contain each 
derivative’s IC50 anti-cancer concentrations (15-19) as well as the MICs against S. aureus, 
E. faecalis and S. pyogenes. 
This study shows some striking similarities amongst the drugs that work against 
cancer cells as well as bacterial cells.  In the case of the original daunomycin, the drug 
demonstrated an IC50 concentration of 33.4 nM in colon cancer SW620 cells as well as 
15.6 nM in leukemia K562 cells.  In addition, daunomycin demonstrated antibacterial 
MIC values of 4 µg/ml in both S. aureus and E. faecalis as well as 0.25 µg/ml in S. 
pyogenes.  When dealing with the newly synthesized anthracycline derivatives in this 
study, Table 3 shows several similarities that, when compared with Table 4, demonstrate 
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the importance of the amino group on the 3’ carbon of the sugar directly attached to the 
anthracycline conjugated ring system.  This discovery is also evident when comparing 
daunomycin (drug 1) with drug 9, in which daunomycin, containing an amine group on 
the 3’ carbon, shows bacterial inhibition while drug 9 with the azido group at the same 
position fails to inhibit bacteria at a concentration below 33 µg/ml.  In the comparison 
between the antibacterial and anticancer effects of the drugs in Table 3, drugs 14, 15, 16, 
18 and 21 seem to demonstrate the greatest clinical potential.  Drug 18 demonstrated 
strong anticancer activity (21.0 nM in leukemia K562 cells) as well as fairly strong 
antibacterial activity (4 µg/ml in S. aureus, 8 µg/ml in E. faecalis and 2 µg/ml in S. 
pyogenes).  When comparing drug 18 to drugs 16 and 17, the linkage between the two 
carbohydrates seems to be more important for the anticancer and antibacterial activity 
than the change on the 3’ carbon of the second carbohydrate.  This is more evident when 
comparing the activities of drug 16 to drug 17.  Drug 16 contains an alpha linkage 
between the disaccharides and showed better anticancer and antibacterial inhibition than 
drug 17, which contains a beta linkage.  Drug 21 demonstrated a slightly higher IC50 
concentration against leukemia K562 cells (31.3 nM) when compared with Drug 18, as 
well as a slightly lower MIC value against E. faecalis (4 µg/ml).  Drugs 15 and 16 
compared fairly well with each other in terms of anticancer activity (45.8 nM and 44.3 
nM against leukemia K562 cells, respectively) but drug 16 seemed to have a lower 
bacterial inhibitory concentration when measured against S. aureus (4 µg/ml) and E. 
faecalis (4 µg/ml), while drug 15 inhibited S. pyogenes slightly better than drug 16 (1 
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µg/ml in drug 15 and 2 µg/ml in drug 16).  The last of the anticancer/antibacterial agents, 
Drug 14, showed fairly good anticancer activity (39.5 nM) as well as fairly good 
antibacterial activity, inhibiting S. aureus at 4 µg/ml, E. faecalis at 8 µg/ml and S. 
pyogenes at 4 µg/ml.  However, when drugs 14 and 15 are compared to each other, the 
linkage between their disaccharides does not seem to be an important factor in bacterial 
or cancer inhibition. 
This structure-activity relationship amongst bacteria and cancer cell lines is also 
evident when looking at Table 6 and the indolocarbazole derivatives.  Beginning with 
drug 36; just as the aglycan version of daunomycin was unable to inhibit either cancer or 
bacterial cell growth, the same is true with the aglycan indolocarbazole derivative.  
When comparing drugs 37 and 42, Table 6 quickly points out the significance of the 
imide nitrogen at the top of the indolocarbazole substituted ring system.  The 
comparison shows that an amino substituent attached to the imide nitrogen, as opposed to 
a methyl or hydrogen substituent, seems to decrease biological activity.  However, in 
terms of cancer cell growth inhibition, drug 38 demonstrates very strong cancer cell 
inhibitions (2 µM); the opposite is observed when this same drug was tested against 
bacteria (> 33 µg/ml). 
It is interesting to note that previous literature on the use of indolocarbazoles 
derivatives and their biological activity has noted that the two chlorine atoms on 
rebeccamycin actually prevents the drug from intercalating with the DNA (20).  In 
addition, the same study mentions that the sugar portion of indolocarbazoles is extremely 
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important in the inhibition of Topoisomerase I.  This was found to be true in the study 
that our lab has conducted when comparing the activities of the aglycan indolocarbazole 
derivative 36 with those containing carbohydrate groups (37-42).  However, the 
literature also points out that indolocarbazoles with a beta-glycosidic linkage seem to be 
the only potent Topoisomerase I inhibitors (20).  In some cases, our study agrees with 
these results when comparing the activity of the beta linked drug 42 and the alpha linked 
drug 39.  On the other hand, our study with bacteria and Dr. Sun’s study with the cancer 
shows at least some inhibitory activity regardless of linkage (as seen with drugs 40 and 
41). 
The potential of these new anticancer drug derivatives to protect a patient from 
obtaining a nosocomial infection mainly depends on the dosage.  After examining which 
of these drugs show the most promise to accomplish this task, drugs 14, 15, 16, 18 and 21 
in particular are disaccharide anthracyclines, proven to have less cardiotoxicity than the 
monosaccharide Daunomycin (23).  For a general estimation of what concentration of 
an antimicrobial agent will be needed to elicit an antibiotic effect on the body, the MIC 
value obtained from in vitro studies is first multiplied by 2-4 times.  The resulting 
concentration is further multiplied by approximately 70% of a patient’s body weight in 
volume (~40 Liters).  When applying these calculations to the anthracyclines 14, 15, 16, 
18 and 21, with an average MIC value of 4 µg/ml, a cumulative dosage of 460 mg would 
be necessary to inhibit bacterial growth in body fluids.  Since these drugs exhibit lower 
cardiotoxicity, they may be used at higher cumulative concentrations than daunomycin 
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(90-360 mg/m2). In the case of the indolocarbazole derivative 40, with an average MIC 
value to 1 µg/ml, general estimates indicate that a cumulative concentration of 120 mg 
would be needed to inhibit bacterial growth.  This estimate in particular seems very 
attractive when noticing that rebeccamycin is used at 16-128 mg/m2/week for several 
weeks, with a maximum tolerated dosage (MTD) of 572 mg/m2.  However, since several 
clinical studies are normally done to discover the ideal dosage for antibiotics, this rough 
estimate should be looked at only as being preliminary. 
In particular, S. pyogenes was observed to be more sensitive to most of the drugs 
tested.  In the case of drugs 8, 10-13, 20 and 23, S. pyogenes was the only one inhibited 
in the study.  Generally, most of the drugs that contain a general inhibitory effect against 
all three gram-positive organisms also show anticancer activity as well.  Due to the 
limited understanding of how anthracyclines and indolocarbazoles work in mammalian 
and bacterial systems, a structural reasoning for the similarities in activity can only be 
created through the testing of more drugs against both classes of organisms.  
Nevertheless, several drugs in this study (particularly drugs 14, 15, 16, 18, 21 and 40) 
may prove to be studied further in the hopes of achieving more pharmaceutical agents 
that minimize nosocomial infections as well as inhibit cancer cell proliferation.   
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